4.08

2.39% -0.10

After Hours: 4.10 0.02 +0.49%

Cytomx Therapeutics Inc (CTMX)

Overview News Price History Option Chain Financials Discussions Forecast

Cytomx Therapeutics Inc stock is traded at $4.08, with a volume of 2.38M. It is down -2.39% in the last 24 hours and down -10.53% over the past month. CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Previous Close:

$4.18

Open:

$4.2

24h Volume:

2.38M

Relative Volume:

0.37

Market Cap:

$888.23M

Revenue:

$76.20M

Net Income/Loss:

$-17.37M

P/E Ratio:

448.35

EPS:

0.0091

Net Cash Flow:

$-75.81M

1W Performance:

-0.97%

1M Performance:

-10.53%

6M Performance:

-3.09%

1Y Performance:

+324.47%

1-Day Range:

$4.04

$4.255

1-Week Range:

$3.99

$4.38

52-Week Range:

$0.9041

$8.21

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name

Cytomx Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

650.515.3185

Address

151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Employee

Twitter

@cytomxinc

Next Earnings Date

2026-05-07

Latest SEC Filings

CTMX's Discussions on Twitter

Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTMX Cytomx Therapeutics Inc	4.08	910.00M	76.20M	-17.37M	-75.81M	0.0091
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Upgrade	JP Morgan	Neutral → Overweight
Jan-20-26	Initiated	Guggenheim	Buy
Sep-22-25	Initiated	Cantor Fitzgerald	Overweight
Sep-17-25	Resumed	Barclays	Overweight
Jul-31-25	Initiated	Oppenheimer	Outperform
May-15-25	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-14-25	Resumed	Piper Sandler	Overweight
May-28-24	Upgrade	Piper Sandler	Neutral → Overweight
May-09-24	Upgrade	Wedbush	Neutral → Outperform
May-06-24	Upgrade	Jefferies	Hold → Buy
Apr-22-24	Upgrade	JP Morgan	Underweight → Neutral
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-07-22	Downgrade	Jefferies	Buy → Hold
Jul-07-22	Downgrade	Mizuho	Buy → Neutral
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Jan-18-22	Upgrade	Barclays	Underweight → Overweight
Nov-15-21	Initiated	BTIG Research	Buy
May-28-21	Downgrade	Barclays	Equal Weight → Underweight
Mar-29-21	Initiated	JP Morgan	Overweight
Mar-23-21	Upgrade	Jefferies	Hold → Buy
Sep-22-20	Downgrade	Guggenheim	Buy → Neutral
Jun-01-20	Downgrade	Jefferies	Buy → Hold
May-14-20	Reiterated	H.C. Wainwright	Buy
Mar-24-20	Upgrade	Wedbush	Neutral → Outperform
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-20-19	Initiated	Guggenheim	Buy
Nov-11-19	Downgrade	Wedbush	Outperform → Neutral
Jun-13-19	Initiated	Mizuho	Buy
May-14-19	Initiated	Cantor Fitzgerald	Overweight
Mar-11-19	Initiated	Barclays	Overweight
Nov-26-18	Initiated	Piper Jaffray	Overweight
Oct-15-18	Initiated	Goldman	Neutral
Sep-13-18	Initiated	H.C. Wainwright	Buy
Jun-01-18	Initiated	SunTrust	Buy
Jan-05-18	Initiated	Citigroup	Buy
Sep-08-17	Initiated	Wedbush	Outperform
Mar-27-17	Initiated	H.C. Wainwright	Buy
Mar-02-17	Initiated	Instinet	Buy
Jan-03-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-02-15	Initiated	Oppenheimer	Outperform

View All

Cytomx Therapeutics Inc Stock (CTMX) Latest News

May 03, 2026

MSN Money - MSN

May 03, 2026

May 02, 2026

CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

May 02, 2026

Apr 30, 2026

Certain Restricted Stock Units of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026. - marketscreener.com

Apr 30, 2026

170,186,365 Common Stock of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026. - marketscreener.com

Apr 30, 2026

CytomX (NASDAQ: CTMX) proxy adds share capacity and expands equity plans - Stock Titan

Apr 30, 2026

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 - Yahoo Finance UK

Apr 30, 2026

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 30, 2026

Apr 27, 2026

HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - MSN

Apr 27, 2026

CytomX stock rises 31% in a month: Here's what you should know - MSN

Apr 27, 2026

Cantor Fitzgerald Initiates Coverage of CytomX Therapeutics (CTMX) with Overweight Recommendation - MSN

Apr 27, 2026

Apr 26, 2026

CytomX Therapeutics launches $250M public offering - MSN

Apr 26, 2026

Apr 25, 2026

Wall Street Zen Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Strong Sell - MarketBeat

Apr 25, 2026

Apr 24, 2026

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat

Apr 24, 2026

Apr 23, 2026

CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN

Apr 23, 2026

CTMX Stock Price, Quote & Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill

Apr 23, 2026

Apr 22, 2026

CTMX (CytomX Therapeutics Inc.) shares climb over 7 percent despite wider than expected Q4 2025 per share losses.Margin of Safety - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Small Cap or Megacap: Which Healthcare Stock Is Right for You? - The Motley Fool

Apr 22, 2026

CTMX Forecast, Price Target & Analyst Ratings | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill

Apr 22, 2026

Apr 21, 2026

Analysts bullish on CytomX Therapeutics (CTMX) as CTMX prices $250 million offering - MSN

Apr 21, 2026

Apr 20, 2026

CytomX (NASDAQ: CTMX) seeks shareholder OK to double authorized shares to 600M - Stock Titan

Apr 20, 2026

CytomX Therapeutics (CTMX) gains analyst confidence on trial progress - MSN

Apr 20, 2026

HC Wainwright & Co. Maintains CytomX Therapeutics (CTMX) Buy Recommendation - MSN

Apr 20, 2026

Apr 19, 2026

CytomX Therapeutics (CTMX) making progress on key metastatic colorectal cancer treatment - MSN

Apr 19, 2026

CytomX Therapeutics Inc Share PriceCTMX, RNS News, Articles, Quotes, & Charts (NASDAQ:CTMX) - Proactive financial news

Apr 19, 2026

Apr 18, 2026

CTMX SEC FilingsCytomx Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 18, 2026

Why CTMX Stock Is Soaring 54% Pre-Market Today? - MSN

Apr 18, 2026

Apr 16, 2026

Point72 (CTMX) reports 10,864,581 shares, a 5.0% holding in CytomX - Stock Titan

Apr 16, 2026

Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX) - MarketBeat

Apr 16, 2026

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 6.3%Time to Buy? - MarketBeat

Apr 16, 2026